Phase 1 Clinical trial of BGE-102 for diseases associated with neuroinflammation such as Obesity.
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs BGE 102 (Primary)
- Indications Inflammation; Obesity
- Focus Adverse reactions
- Sponsors BioAge Labs
- 04 Feb 2025 New trial record
- 28 Jan 2025 According to BioAge Labs Media release, IND-enabling experiments for BGE-102 are currently underway, and Phase 1 SAD clinical data are anticipated by the end of 2025.